## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 10/632,150						
APPLICANT Chiaur et al.						
filing date July 30, 2003	GROUP 1632					

	U.S. PATENT DOCUMENTS				
		Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figure Appear	
	A01	4,873,191	10/10/89	Wagner et al.	
	A02	5,093,246	3/3/92	Cech et al.	
	A03	5,519,003	5/21/96	Mochly-Rosen et al.	
A04 5,981,702 11/ 9/99		Zhang et al.			

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 00/34447	06/15/00	Signal Pharm Inc and Yissum Res Dev Co		
	B02	WO 89/10134	04/25/89	Univ California		
	B03	WO 95/21252	08/10/95	Univ Leland Stanford Junior		
	B04	WO 97/11176	03/27/97	Cold Spring Harbor Lab)		
	B05	WO 99/18989	04/22/99	Baylor College Medicine		
	B06	WO 99/31252	12/2/98	Incyte Pharma Inc		
	B07	WO 99/38969	08/5/99	Inst Nat Sante Rech Med and Pasteur Institut		
	B08	WO 00/22110	04/20/00	Harvard College		
	B09	WO 00/77207	12/21/00	The Burnham Institute		
	B10	WO 00/12679	3/9/00	New York University		
	B11	WO 01/75067	10/11/01	Hyseq, Inc.		
	B12	WO 01/92525	12/6/01	Corixa Corporation		
	B13	WO 02/55665	7/18/02	New York University		

*Examiner Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, Initials serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C01	BAI et al., 1996, "SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box," Cell 86:263-274	
CARRANO et al., 1999, "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibit Nature Cell Biol. 1:193		CARRANO et al., 1999, "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27," Nature Cell Biol. 1:193	******
	C03	CENCIARELLI et al., 1999, "Identification of a family of human F-box proteins," Curr. Biol. 9:1177-1179	
C1ECHANOVER, 1994, "The ubiquitin-proteasome proteolytic pathway," Cell 79:13-21		CIECHANOVER, 1994, "The ubiquitin-proteasome proteolytic pathway," Cell 79:13-21	
	C05	CIECHANOVER, 1998, "The ubiquitin-proteasome pathway: on protein death and cell life," EMBO J. 17:7151	

	ATTY DOCKET NO.	APPLICATION NO
	5914-098-999	10/632,150
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Chiaur et al.	
	FILING DATE	GROUP
	July 30, 2003	1632

		NON PATENT LITERATURE DOCUMENTS	
*Examiner Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, maga serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country w			T
	C06	DESHAIES, 1999, "SCF and Cullin/Ring H2-based ubiquitin ligases, " Ann. Rev. Cell Dev. Biol. 15:435-67	
	C07	ESPOSITO et al., 1997, "Prognostic role of the cell cycle inhibitor p27 in non-small cell lung cancer.,"  Cancer Research 57:3381-3385	
	C08	GONEN et al., 1999, "Identification of the ubiquitin-carrier proteins, E2s, involved in signal-induced degradation of IκBα," J. Biol. Chem. 274:14823-14830	
	C09	HOCHSTRASSER, 1995, "Ubiquitin, proteasomes, and the regulation of intracellular protein degradation," Curr. Op. Cell Biol. 7:215-223	
	C10	HUNTER and PINES, 1994, "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," Cell 79:573	
	C11	JIANG and STRUHL, 1998, "Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb," Nature 29:391:493-496	
	C12	KAISER et al., 1998, "Cdc34 and the F-box protein Met30 are required for degradation of the Cdk-inhibitory kinase Swe1," Genes Dev. 12(16):2587-2597	
	C13	KEYOMARSI et al., 1995, "Deregulation of cyclin E in breast cancer," Oncogene 11:941-950	
	C14	KIPREOS et al., 1996, "cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family," Cell 85:829	
	C15	KOCH et al., 1991, "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," Science 252:668-674	
	C16	KOEPP et al., 1999, "How the cyclin became a cyclin: regulated proteolysis in the cell cycle, " Cell. 97:431-433	***************************************
	C17	LANDSCHULTZ et al., 1988, "The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins," Science 240:1759-1764	***************************************
	C18	LATRES et al., 2001, "Role of the F-box protein Skp2 in lymphomagenesis," Proc. Natl. Acad. Sci. USA 98:2515-2520	
	C19	LATRES, 1999, "The human F box protein β-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin," Oncogene 18:849-854	
	C20	LLOYD, 1999, "p27 <sup>kip1</sup> : a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers," Am. J. Pathol. 154:313-323	
	C21	LODA et al., 1997, "Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas," Nature Medicine 3:231-234	***************************************
	C22	LYAPINA, 1998, "Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein," Proc. Natl. Acad. Sci. USA 95:7451-7476	
	C23	MARGOTTIN et al., 1998, "A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif," Molecular Cell 1:565-574	
	C24	MARIKAWA and ELINSON, 1998, "β-TrCP is a negative regulator of <i>Wnt'β-catenin</i> signaling pathway and dorsal axis formation in <i>Xenopus</i> embryos," Mech. Dev. 77(1):75-80	
*****	C25	MONTAGNOLI et al., 1999, "Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation," Genes and Dev. 13:1181	
	C26	NEER et al., 1994, "The ancient regulatory-protein family of WD-repeat proteins," Nature 371:297-300	
	C27	OHTSUBO et al., 1995, "Human cyclin E, a nuclear protein essential for the G <sub>1</sub> -to-S phase transition," Cell Biol. 15:2612-2624	
	C28	PAGANO et al., 1992, "Association of cdk2 kinase with the transcription factor E2F during S phase," Science 255:1144-1147	

	ATTY DOCKET NO. 5914-098-999	APPLICATION NO 10/632,150	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Chiaur et al.		
	FILING DATE July 30, 2003	GROUP 1632	

		NON PATENT LITERATURE DOCUMENTS	
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	C29	PAGANO et al., 1992, "Cyclin A is required at two points in the human cell cycle" EMBO J.: 11(3):961-971	
	C30	PAGANO et al., 1995, "Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27," Science 269:682-685	
	C31	PAGANO, 1993, "Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts," J. Cell Bio. 121:101-111	
	C32	PAGANO, 1995, "From peptide purified antibody," in Cell Cycle: Materials and Methods, M. Pagano, ed., Spring-Verlag, pp. 217-281	
	C33	PAGANO, 1997, "Cell cycle regulation by the ubiquitin pathway," FASEB J. 11:1067-1075	
	C34	PATTON et al., 1998, "Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis," Trends Genet. 14(6):236-243	
	C35	PEIFER, 1997, "β-catenin as oncogene: the smoking gun," Science 275:1752-1753	
	C36	PORTER et al., 1997, Expression of cell-cycle regulators p27 <sup>Kip1</sup> and cyclin E, alone and in combination, correlate with survival in young breast cancer patients," Nature Medicine 3:222	
	C37	ROLFE et al., 1997, "The ubiquitin-mediated proteolytic pathway as a therapeutic area," J. Mol. Med. 75:5-17	
	C38	SHEAFF et al., 1997, "Cyclin E-CDK2 is a regulator of p27 <sup>Kip1</sup> ," Genes Dev. 11:1464-1478	
	C39	SHERR and ROBERTS, 1995, "Inhibitors of mammalian G <sub>1</sub> cyclin-dependent kinases.," Genes Dev. 9:1149-1163	
	C40	SHERR and ROBERTS, 1999, "CDK inhibitors: positive and negative regulators of G <sub>1</sub> -phase progression," Genes & Dev.13(12):1501-1512	
	C41	SINGH et al., 1998, "Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma," Cancer Research 58:1730-1735	
	C42	SKOWYRA et al., 1997, "F-box proteins are receptors that recruit phosphorylated substrates to the SCP-ubiquitin-ligase complex," Cell 91:209-219	
	C43	SPATARO, 1998, "The ubiquitin-proteasome pathway in cancer," Br. J. Cancer 77:448-455	
	C44	TAN et al., 1997, "The cell cycle inhibitor p27 is an independent marker in small (T <sub>1a,b</sub> ) invasive breast carcinomas," Cancer Research 57:1259-1263	
	C45	THOMAS et al., 1998, "Downregulation of p27 is associated with development of colorectal adenocarcinoma metastases," Am. J. Pathol. 153:681-687	
	C46	WINSTON et al., 1999, "A family of mammalian F-box proteins," Curr. Biol. 9:1180-1182	
	C47	WINSTON et al., 1999, "The SCF $^{\beta$ -TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in I $\kappa$ B $\alpha$ and $\beta$ -catenin and stimulates I $\kappa$ B $\alpha$ ubiquitination in vitro," Genes Dev. 13:270-283	
	C48	www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Accession No. AF129532 (Homo sapiens chromosome 13 F-box protein Fbl3a (FBL3A) mRNA, partial cds) Database [Online]. Accessed on March 9, 2001. Released from GenBank on October 31, 1999	
	C49	www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Accession No. AF17621 (Mus musculus leucine-rich repeat-containing F-box protein FBL3a mRNA, partial cds) Database [Online]. Accessed on March 9, 2001. Released from GenBank on December 6, 1999	
	C50	YARON et al., 1998, "Identification of the receptor component of the IκBα-ubiquitin ligase," Nature 396:590-594	

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO. 5914-098-999	APPLICATION NO 10/632,150				
APPLICANT Chiaur et al.					
FILING DATE July 30, 2003	GROUP 1632				

NON PATENT LITERATURE DOCUMENTS				
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  ZACHARIAE and NASMYTH, 1999, "Whose end is destruction: cell division and the anaphase-promoting complex," Genes Dev. 13:2039-58	<u> </u>	
	C52	ZHANG et al., 1995, "p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase," Cell 82:915-925		
	C53	www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) Genbank Accession No. AF126028 (Homo sapiens unknown mRNA), Release from Genbank on March 5, 2000		
	C54	www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) Genbank Accession No. AC001226 (Genomic sequence from Human 13, complete sequence), Release from Genbank on May 29, 1997		
	C55	HAMMER et al., 1990, "Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders", Cell. 63(5):1099-1112		
	C56	SEAMARK RF, 1994, "Progress and emerging problems in livestock transgenesis: a summary perspective", Reprod Fertil Dev. 1994;6(5):653-657		
	C57	CHIAUR et al., 2000, "Five human genes encoding F-box proteins: chromosome mapping and analysis in human tumors", Cytogenet Cell Genet. 88(3-4):255-258		
	C58	MULLINS et al., 1993, "Transgenesis in nonmurine species", Hypertension. 22(4):630-633		
	C59	CAMERON ER., 1997, "Recent advances in transgenic technology", Mol Biotechnol. 7(3):253-265		
	C60	RUDINGER, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in <i>Peptide Hormones</i> , JA Parsons Ed., Nat'l Inst. for Medical Research, Mill Hill, London, pp 1-7		
	C61	CHISSOE et al., 1995, "Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation," Genomics. 27(1):67-82		
	C62	DUFF et al., 1992, "Secondary structure analysis identifies a putative mouse protein demonstrating similarity to the repeat units found in CDC4, the G protein beta subunits and related proteins," DNA Seq. 3(4):213-220		
	C63	HSU et al., 2002, "E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1)," Nat Cell Biol. 4(5):358-366		
	C64	NAGASE et al., 1998, "Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro," DNA Res. 5(6):355-364		
	C65	REIMANN et al., 2001, "Emi1 regulates the anaphase-promoting complex by a different mechanism than Mad2 proteins," Genes Dev. 15(24):3278-3285		
	C66	REIMANN et al., 2001, "Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex," Cell. 105(5):645-655		
	C67	REIMANN et al., 2002, "Emi1 is required for cytostatic factor arrest in vertebrate eggs," Nature. 416(6883):850-854		
	C68	www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) Genbank Accession No. Z45775 (HSCZTG121 normalized infant brain cDNA Homo sapiens cDNA clone c-ztg12, mRNA sequence), Released from Genbank on Nov. 14, 1994		
	C69	www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) Genbank Accession No. Z43904 (HSC1NG091 normalized infant brain cDNA Homo sapiens cDNA clone c-1ng09, MRNA sequence), Released from Genbank on Nov. 14, 1994		

EXAMINER	DATE CONSIDERED
*EXAMINED: Initial if reference concidered, whether or not citation is in conformer	ADED 600: Drowling through situation if and in the

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.